United States: The FTC's First Loss In Nearly Half A Decade, Illuminating The Difficulties Of Prediction And The Merits Of Litigating It

"Prophesy is a good line of business, but it is full of risks." Mark Twain could have been speaking about the FTC's recent challenge to a merger between the second- and third-largest sterilization companies in the world, Steris Corporation and Synergy Health. FTC v. Steris Corp., 2015 WL 5657294 (N.D. Ohio 2015).However, for the first time in four years, the FTC's bid for a preliminary injunction was denied.The FTCargued it had enough evidence to show the merger would have harmed competition in the future, but the court found there were too many uncertainties to support the FTC's prophecy. After the defeat, the FTC announced it would not appeal the decision, and last week, it withdrew its challenge to the Steris-Synergy merger. While one loss is not a trend, it cannot be said that the government always wins.

Potential Competition in Innovation Markets

The FTC challenged the Steris-Synergy merger under a theory called "potential competition," which is used to challenge mergers in innovation markets. Though the theory is somewhat controversial – innovation has been described as "one of the most heated discussions in economic circles"1 – the FTC has not shied away. It has been bringing innovation market cases since the 1970s, and gave innovation markets formal recognition in the 1995 Antitrust Guidelines for the Licensing of Intellectual Property.

As for the potential competition theory, the 2010 Merger Guidelines describe it as applicable "if one of the merging parties has a strong incumbency position and the other merging firm threatens to disrupt market conditions with new technology or business model, their merger can involve the loss of actual or potential competition."To secure a preliminary injunction under a potential competition theory in Steris, the FTC had to demonstrate that "absent the acquisition, the evidence shows that Synergy probably would have entered the U.S. contract sterilization market by building one or more X-ray facilities within a reasonable period of time."In other words, the FTC had to show it was reasonably plausible that market entrance would have occurred in the future, but for the merger.

Most antitrust disputes deal in predictive analysis of some kind, often in predicting what the "but for" world would look like absent challenged conduct. And in modern antitrust practice, these predictions often rely heavily on experts and economic analysis. Predicting whether a merger would have an anticompetitive effect on technological innovation or future market entrance, however, relies more on factual inferences than economic analysis. As former FTC Chairman Timothy Muris said in 2004, "economic theory and empirical investigations have not established a general causal relationship between innovation and competition [so] a careful, intense factual investigation is necessary."2

Still, the FTC has taken particular note of innovation markets in recent years. While it has focused on generic pharmaceutical mergers, italso has branched out to other markets such as automotive starter-ignition markets.

Synergy's Quest for X-ray Sterilization

In the Steris case, the FTC argued Synergy was likely to enter the U.S. market with a new, innovative X-ray sterilization technology. The U.S. market is dominated by a duopoly offering gamma sterilization, and during the years leading up to the announced merger with Steris, Synergy had been pursuing the development of X-ray sterilization facilities in the United States. The new technology would offer customers a cheaper alternative to gamma sterilization. No one else was doing it in the United States, and Synergy believed it could offer sterilization services to its customers – mostly manufacturers of medical equipment – for a lower cost.

But in a fact-intensive decision, the court found the FTC could not meet its burden for two main reasons: 1) customer reluctance to adopt a new, untested technology; and 2) Synergy's internal, risk-averse capital project protocols.

There was no question Synergy wanted to bring X-ray sterilization technology to the U.S. It contracted with a manufacturer (IBA) to build a first-of-its-kind combination gamma and X-ray sterilization machine that could handle the capacity Synergy required. And it reached out to key customers to secure contracts.

But market forces were countervailing, and Synergy scrapped the project four months after announcement of the merger. First, its overtures to customers were met with "academic" interest but no desire to commit to the new technology. There were too many unknowns to switch away from the time-tested gamma method, and Synergy was unable to secure commitment from a single customer.

Second, IBA began expressing doubts it could build the X-ray machine. By the time of the merger, the machine still "had never been designed, built, tested or priced." In the end, the project was never even presented to Synergy's PLC Board, whose approval was required, because it "failed every one of the metrics Synergy uses to rank capital investments."

While the FTC argued it was telling that the X-ray business was scrapped only after announcement of the merger, the court focused on Synergy's continued efforts to make the X-ray business plan work.The court found that "the evidence demonstrates that this was not a sham to convince the FTC that Synergy wanted to enter the market; it was a legitimate effort by Synergy employees who really wanted the project to succeed, but recognized the hurdles they needed to overcome to win approval."

The Future of Merger Challenges in Innovation Markets

The decision is unlikely to avert the FTC's focus from innovation markets, or reduce its willingness to pursue potential competition theories. But the decision shows that potential competition cases are indeed fact-intensive, and a careful marshaling and analysis of evidence can win the day, particularly where, as in the Steris case, the innovation in question is still multiple steps away from approval. When the FTC comes knocking, careful analysis is required, and the first reaction may not just be how to negotiate a settlement but how to win.

Footnotes

1 Michael A. Carrier, Two Puzzles Resolved: Of the Schumpeter-Arrow Stalemate and Pharmaceutical Innovation Markets, 93 Iowa L. Rev. 393, 399 n.8 (2008)

2 Statement of Chairman Timothy J. Muris in the matter of Genzyme Corporation / Novazyme Pharmaceuticals, Inc., available here.

The FTC's First Loss in Nearly Half a Decade, Illuminating the Difficulties of Prediction and the Merits of Litigating It

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.